Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.17, Iss.12, 2008-12, pp. : 1937-1945

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Edoxaban: A New Oral Direct Factor Xa Inhibitor

By Camm A. John

Drugs, Vol. 71, Iss. 12, 2011-08 ,pp. : 1503-1526

Adis International

Access to resources Recommend Favorite

Rivaroxaban, the first oral, direct factor Xa inhibitor

By Fassiadis Nicholas

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 18, 2009-12 ,pp. : 2945-2946

Informa Healthcare

Access to resources Recommend Favorite

Rivaroxaban, an oral direct factor Xa inhibitor

By Piccini Jonathan P Patel Manesh R Mahaffey Kenneth W Fox Keith AA Califf Robert M

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 6, 2008-06 ,pp. : 925-937

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of the oral direct factor Xa inhibitor – betrixaban

By Palladino Michael Merli Geno Thomson Lynda

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 11, 2013-11 ,pp. : 1465-1472

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics and Pharmacodynamics of Rivaroxaban – An Oral, Direct Factor Xa Inhibitor

Current Clinical Pharmacology, Vol. 9, Iss. 1, 2014-02 ,pp. : 75-83

Bentham Science Publishers

Access to resources Recommend Favorite